Adaptimmune Therapeutics logo

ADAP - Adaptimmune Therapeutics News Story

$4.8 0.0  0.4%

Last Trade - 4:35pm

Sector
Healthcare
Size
Mid Cap
Market Cap £525.6m
Enterprise Value £300.8m
Revenue £2.57m
Position in Universe 3130th / 6853

Adaptimmune to Report Fourth Quarter/ Full Year 2020 Financial Results and Business Updates on Thursday, February 25, 2021

Thu 11th February, 2021 1:00pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210211:nGNX4TbZTH&default-theme=true


PHILADELPHIA and OXFORDSHIRE, United Kingdom, Feb. 11, 2021 (GLOBE NEWSWIRE)
-- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to
treat cancer, will report financial results and provide business updates for
the fourth quarter and year ended December 31, 2020, before the US markets
open on Thursday, February 25, 2021. Following the announcement, the Company
will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT)
that same day (details below).

The press release and the live webcast of the conference call will be
available in the investor section of Adaptimmune’s corporate website
at www.adaptimmune.com. An archive will be available after the call at that
same address.

To participate in the live conference call, please dial (833) 652-5917 (U.S.
or Canada) or +1 (430) 775-1624 (International). After placing the call,
please ask to be joined into the Adaptimmune conference call and provide the
confirmation code (2099860).

About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on the
development of novel cancer immunotherapy products for people with cancer. The
Company’s unique SPEAR(®) (Specific Peptide Enhanced Affinity Receptor)
T-cell platform enables the engineering of T-cells to target and destroy
cancer across multiple solid tumors.

Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties. Such risks
and uncertainties could cause our actual results to differ materially from
those indicated by such forward-looking statements, and include, without
limitation: the success, cost and timing of our product development activities
and clinical trials and our ability to successfully advance our TCR
therapeutic candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could cause our
actual results to differ materially from those expressed in these
forward-looking statements, as well as risks relating to our business in
general, we refer you to our Quarterly Report on Form 10-Q filed with the SEC
on November 5, 2020, and our other SEC filings. The forward-looking statements
contained in this press release speak only as of the date the statements were
made and we do not undertake any obligation to update such forward-looking
statements to reflect subsequent events or circumstances.

Adaptimmune Contacts:

Media Relations:

Sébastien Desprez — VP, Communications and Investor Relations
T: +44 1235 430 583
M: +44 7718 453 176
Sebastien.Desprez@adaptimmune.com

Investor Relations:

Juli P. Miller, Ph.D. — Senior Director, Investor Relations
T: +1 215 825 9310
M: +1 215 460 8920
Juli.Miller@adaptimmune.com


(https://www.globenewswire.com/NewsRoom/AttachmentNg/f61dc272-2f81-43b4-97ce-b387507030db)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.